Serial visualization of Glucose-insulin metabolism in thin young Indians with prediabetes reveals early failure of beta cell secretion in relation to decreasing insulin sensitivity - Tiwari, Pradeep; Phatak, Sanat; Bandopadhyay, Souvik; Sethi, Tavpritesh; Fall, Caroline HD; Yajnik, Chittaranjan (medRxiv, 2022)
Background & Objective Defective beta cell function in relation to impaired insulin sensitivity results in glucose intolerance. There are few studies documenting the lifecourse evolution of this relationship. The Pune Maternal Nutrition Study (PMNS) longitudinal birth cohort offered the opportunity to document these parameters from childhood in young, rural prediabetic participants and compare them to normal glucose tolerant (NGT).Methods PMNS subjects were classified as NGT or Glucose intolerant according to their OGTT results at 18 years of age. Insulin Sensitivity (HOMA-S) and β-cell function (HOMA-β) were estimated at 6,12 and 18 years. Their inter-relationship was estimated using HOMA-β as a nonlinear function of HOMA-S, separately for NGT and Glucose intolerant individuals at 6,12 and 18 years. Rates of change of HOMA-S and HOMA-β were estimated using a linear mixed effect model and visualized using LOESS plots.Result Of 619 participants, 177 had glucose intolerance at 18 years of age. A nonlinear hyperbolic relationship between HOMA-S and HOMA-B was observed at all time points. There was a progressive fall in HOMA-S and rise in HOMA-B with increasing age. Glucose intolerant participants had lower HOMA-B for all levels of HOMA-S as compared to NGT, manifesting as shift towards the origin in the hyperbolic curve.Conclusion We provide evidence for early life dysregulation in glucose insulin metabolism leading to pre-diabetes at 18 years of age. Prediabetic individuals started with lower beta cell function and lower insulin sensitivity from an early age. Diabetes prevention should start from early life.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe PMNS was funded by the Wellcome Trust, London, U.K. (038128/Z/93, 059609/Z/99, 079877/Z/06/Z, 098575/B/12/Z, and 083460/Z/07/Z), Medical Research Council, U.K. (MR/J000094/1), Department of Biotechnology, Government of India (BT/PR-6870/PID/20/268/2005) and Department of Science and Technology, Government of India (DST/ICPS/EDA/2018). Between these grants, the study was funded intramurally (KEM Hospital Research Centre).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of KEM Hospital Research Centre gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the study are available on reasonable request to Prof Chittaranjan Yajnik